Most risk algorithms for assessing the likelihood of a BRCA1/2 mutation were developed before the ability to adjust for pathology, particularly relevant for BRCA1 where the majority of breast cancers are high grade and triple negative (estrogen receptor (ER), progesterone receptor (PR) and HER2 negative) [4–8]. Here, PGR is linked to breast cancer.